Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05181748 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders

Study acronym: PRPPOR
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2027
    • Study completion date: Jan 31, 2026 to Dec 31, 2028
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Primary completion date: Dec 31, 2023 to Dec 31, 2025
    • Study completion date: Jan 31, 2024 to Jan 31, 2026
    v3
  4. Primary endpoints revised (2)
    • Secondary endpoints revised (2)
    • Eligibility criteria expanded, about 2 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Autologous platelet rich plasma (PRP) intraovarian infusion may improve ovarian response to controlled ovarian stimulation as well as the hormonal profile of poor ovarian response infertile women subjected to intracytoplasmic sperm injection (ICSI) treatment.
Trial Details
NCT Number NCT05181748
Lead Sponsor Genesis Athens Clinic
Collaborators: National and Kapodistrian University of Athens
Conditions
(from sponsor)		 Poor Response to Ovulation Induction, Infertility, Female, Ovarian Insufficiency, Ovarian Failure, Reproductive Sterility, Ovary; Anomaly
Related terms Congenital Abnormalities, Infertility, Infertility, Female
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov